An interventional study of Nail Genesis DLSO Product and Nail Genesis DLSO Product (vehicle only) in Distal Lateral Subungual Onychomycosis and Onychomycosis, sponsored by Nail Genesis LLC. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-08.
Sponsored by Nail Genesis LLC · Not applicable, Interventional, and Treatment
This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle.
Subject eligibility will be determined during a Screening assessment. Subjects will complete a 4week washout period after discontinuation of a topical product or a 12-month washout period after discontinuation of an oral product or light-based therapy prior to randomization. Eligible subjects will be randomized in a 2:1 ratio to receive Nail Genesis DLSO Product or vehicle, respectively. During the 52-week trial, study medication will be administered once daily to the target toenail for 48 weeks.
A subject will be considered to have completed the study when he or she has completed the study assessments at Week 52. The 52-week visit is for follow-up safety assessments.
147 studies on the registry are indexed under Onychomycosis; 13 are open to participants now.
This study's planned enrollment of 338 is above the median of 56 across 134 interventional studies indexed under Onychomycosis.
Browse Onychomycosis studies →This is the only study on the registry with Nail Genesis LLC as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Nail Genesis DLSO Product, poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
Device: Nail Genesis DLSO Product
poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
Device: Nail Genesis DLSO Product (vehicle only)
Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
The Nail Genesis DLSO product poly-urethane vehicle
Effectiveness - Complete Cure
Proportion of subjects with Complete Cure (0% involvement of the target toenail in addition to Mycologic Cure (defined as both negative KOH stain and negative dermatophyte culture).
Time frame: Week 48
Safety - Adverse Events
Proportion of subjects with treatment-emergent AEs of Nail Genesis DLSO Product compared with vehicle control)
Time frame: Week 48
Almost complete cure
Proportion of subjects achieving almost Complete Cure (\< 10% clinical involvement of the target toenail) in addition to Mycologic Cure.
Time frame: Week 48
Mycological Cure
Proportion of subjects achieving Mycologic Cure of the target toenail at Week 48
Time frame: Week 48
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.